Aktis To Present Clinical Imaging And Dosimetry Data For AKY-2519 In Treating MCRPC Next Month

Aktis Oncology will present clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting solid tumors in metastatic prostate cancer, at the 2026 annual meeting of the American Society of Clinical Oncology. The update is informational and early-stage, with no trial results, regulatory milestone, or commercial data disclosed. The news is likely to be of limited near-term market impact.

Analysis

Aktis Oncology will present clinical imaging and dosimetry data for AKY-2519, a miniprotein radioconjugate targeting solid tumors in metastatic prostate cancer, at the 2026 annual meeting of the American Society of Clinical Oncology. The update is informational and early-stage, with no trial results, regulatory milestone, or commercial data disclosed. The news is likely to be of limited near-term market impact.